Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 6/20 | 0.74 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | FPR2 | P25090 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4697246 | 0.87 | HSD11B1 (0.61) | HSD11B1POLBSMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL3548392 | 0.87 | HSD11B1 (0.76) | HSD11B1CES2ALDH1A1MCOLN3KMT2A | |
| SCHEMBL3548948 | 0.86 | HSD11B1 (0.74) | HSD11B1TSHRLMNA | |
| SCHEMBL14365000 | 0.86 | HSD11B1 (0.74) | HSD11B1CES2SMN1; SMN2ALDH1A1MCOLN3 | |
| SCHEMBL2986964 | 0.85 | HSD11B1 (1.00) | HSD11B1CES2SMN1; SMN2ALDH1A1MCOLN3 | |
| SCHEMBL3542808 | 0.83 | HSD11B1 (0.84) | HSD11B1CES2SMN1; SMN2ALDH1A1MCOLN3 | |
| SCHEMBL4506529 | 0.83 | HSD11B1 (0.74) | HSD11B1ALDH1A1KMT2A | |
| SCHEMBL4513154 | 0.82 | HSD11B1 (0.69) | HSD11B1POLBCES2SMN1; SMN2HPGD | |
| SCHEMBL4517638 | 0.82 | HSD11B1 (0.73) | HSD11B1SMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL3554688 | 0.82 | HSD11B1 (0.69) | HSD11B1POLBTSHRSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
| EP-1864971-A1 | PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES | Takeda Pharmaceutical Company Limited (JP) | 2007-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | HSD11B1, HSD17B1, HSD11B2 | HSD11B1 1/4885POLB 2628/4885CES2 476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.